Platelet Biogenesis Inc., of Cambridge, Mass., signed a $56 million contract with the Biomedical Advanced Research and Development Authority to develop donor-independent platelets as a medical countermeasure for treatment of thrombocytopenia in victims of a nuclear or radiological event.